Pattern of HCV antibodies with special reference to NS5A reactivity in HCV-infected patients: relation to viral genotype, cryoglobulinemia and response to interferon

被引:21
|
作者
Frangeul, L
Cresta, P
Perrin, M
Duverlie, G
Khorsi, H
Musset, L
Opolon, P
Huraux, JM
Lunel, F
机构
[1] CHU Pitie Salpetriere, Serv Virol, F-75651 Paris 13, France
[2] CHU Pitie Salpetriere, Serv Hepatogastroenterol, F-75651 Paris, France
[3] CHU Pitie Salpetriere, Serv Immunochim, F-75651 Paris 13, France
[4] CHU Hop Sud, Serv Virol, Amiens, France
[5] Hop Angers, Serv Bacteriol Virol, Angers, France
关键词
anti-HCV antibodies; cryoglobulinemia; hepatitis C virus; interferon; interferon sensitivity determining region (ISDR); NS5A;
D O I
10.1016/S0168-8278(98)80275-4
中图分类号
R57 [消化系及腹部疾病];
学科分类号
摘要
Background/Aims: We aimed to compare the antihepatitis C virus reactivity in confirmatory assays (RIBA 3.0 (C)Ortho Diagnostic and INNO-LIA HCV Ab III (C)Innogenetics) among patients infected with different hepatitis C virus genotypes, with or without cryoglobulinemia, and in patients treated with interferon, Methods: One hundred and three patients followed in our hepatogastroenterology unit were included in the study and compared to 320 consecutive patients tested using RIBA 3.0, Seventy-nine of the 103 patients were treated,vith interferon. Long-term responders to interferon were defined as having normal alanine aminotransferase levels and being HCV RNA negative 6 months after the end of treatment, Initial responders mere defined as having normal alanine aminotransferase levels at the end of interferon therapy but abnormal alanine aminotransferase levels and/or detectable HCV RNA during the following 6 months. Non-responders mere defined as still having elevated alanine aminotransferase during and after interferon, Serological tests (RIBA and INNO-LIA) were performed according to the manufacturers' instructions. HCV RNA was detected by nested polymerase chain reaction. Hepatitis C virus genotype was determined by using a Line Probe Assay ((C)Innogenetics). Results: There was no significant difference in the pattern of hepatitis C virus reactivity according to the hepatitis C virus genotype or presence of cryoglobulinemia. Twenty-three patients were classified as nonresponders, 35 as initial responders, 21 as long-term responders, NS5 reactivity was significantly different (p<0.01) between these three groups: 34% of non-responders (8/23) had RIBA 3.0 NS5 reactivity and 13% (3/23) were reactive in the INNO-LIA III. Almost all long-term responders (95%) had NS5 reactivity by both RIBA 3.0 and INNO-LIA III. Conclusion: We conclude that patients who respond to interferon have stronger reactivity against NS5 antigens than non-responders, Molecular changes in the NS5A region may be responsible for such differences, as recently suggested.
引用
收藏
页码:538 / 543
页数:6
相关论文
共 37 条
  • [1] HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in Mainland China
    Wei, Lai
    Omata, Masao
    Lim, Young-Suk
    Xie, Qing
    Hou, Jin Lin
    Jia, Jidong
    Hedskog, Charlotte
    Martin, Ross
    Doehle, Brian
    Yang, Jenny
    De-Oertel, Shampa
    Massetto, Benedetta
    Kersey, Kathryn
    Brainard, Diana M.
    Svarovskaia, Evguenia
    Mo, Hongmei
    Han, Kwang-Hyub
    Mizokami, Masashi
    Duan, Zhongping
    ANTIVIRAL RESEARCH, 2018, 158 : 178 - 184
  • [2] Prevalence of hepatitis C virus (HCV) variants resistant to NS5A inhibitors in naive patients infected with HCV genotype 1 in Tunisia
    Larousse, Jameleddine Aissa
    Trimoulet, Pascale
    Pinson, Patricia Recordon
    Tauzin, Brigitte
    Azzouz, Mohamed Mssadak
    Ben Mami, Nabyl
    Cheikh, Imed
    Triki, Henda
    Fleury, Herve
    VIROLOGY JOURNAL, 2015, 12
  • [3] NS5A protein of HCV enhances HBV replication and resistance to interferon response
    Pan, Ying
    Wei, Wei
    Kang, Lei
    Wang, Zhongqiang
    Fang, Jiali
    Zhu, Ying
    Wu, Jianguo
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2007, 359 (01) : 70 - 75
  • [4] NS5A Gene Analysis by Next Generation Sequencing in HCV Nosocomial Transmission Clusters of HCV Genotype 1b Infected Patients
    Bellocchi, Maria Concetta
    Aragri, Marianna
    Carioti, Luca
    Fabeni, Lavinia
    Pipitone, Rosaria Maria
    Brancaccio, Giuseppina
    Sorbo, Maria Chiara
    Barbaliscia, Silvia
    Di Maio, Velia Chiara
    Bronte, Fabrizio
    Grimaudo, Stefania
    Mazzucco, Walter
    Frigeri, Ferdinando
    Cantone, Marco
    Pinto, Antonio
    Perno, Carlo Federico
    Craxi, Antonio
    Gaeta, Giovanni Battista
    Di Marco, Vito
    Ceccherini-Silberstein, Francesca
    CELLS, 2019, 8 (07)
  • [5] The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment
    Suda, Goki
    Nakai, Masato
    Sho, Takuya
    Kimura, Megumi
    Shimazaki, Tomoe
    Maehara, Osamu
    Shigesawa, Taku
    Suzuki, Kazuharu
    Nakamura, Akihisa
    Ohara, Masatsugu
    Umemura, Machiko
    Kawagishi, Naoki
    Baba, Masaru
    Natsuizaka, Mitsuteru
    Morikawa, Kenichi
    Ogawa, Koji
    Sakamoto, Naoya
    INTERNAL MEDICINE, 2019, 58 (07) : 943 - 947
  • [6] Prevalence of hepatitis C virus (HCV) variants resistant to NS5A inhibitors in naïve patients infected with HCV genotype 1 in Tunisia
    Jameleddine Aissa Larousse
    Pascale Trimoulet
    Patricia Recordon Pinson
    Brigitte Tauzin
    Mohamed Mssadak Azzouz
    Nabyl Ben Mami
    Imed Cheikh
    Henda Triki
    Hervé Fleury
    Virology Journal, 12
  • [7] Response to combination therapy of HCV 3a infected Pakistani patients and the role of NS5A protein
    Ali, Ijaz
    Khan, Sanaullah
    Attaullah, Sobia
    Khan, Shahid Niaz
    Khan, Jabbar
    Siraj, Sami
    Iqbal, Aqib
    Swati, Zahoor A.
    Idrees, Muhammad
    VIROLOGY JOURNAL, 2011, 8
  • [8] Mutations in the NS5A gene of hepatitis C virus in North American patients infected with HCV genotype 1a or 1b
    Hofgartner, WT
    Polyak, SJ
    Sullivan, DG
    Carithers, RL
    Gretch, DR
    JOURNAL OF MEDICAL VIROLOGY, 1997, 53 (02) : 118 - 126
  • [9] Relation of pretreatment sequence diversity in NS5A region of HCV genotype 1 with immune response between pegylated-INF/ribavirin therapy outcomes
    de Queiroz, A. T. L.
    Maracaja-Coutinho, V.
    Jardim, A. C. G.
    Rahal, P.
    de Carvalho-Mello, I. M. V. G.
    Matioli, S. R.
    JOURNAL OF VIRAL HEPATITIS, 2011, 18 (02) : 142 - 148
  • [10] Characterization of NS5A polymorphisms and their impact on response rates in patients with HCV genotype 2 treated with daclatasvir-based regimens
    Zhou, Nannan
    Han, Zhou
    Hartman-Neumann, Sandra
    DeGray, Brenda
    Ueland, Joseph
    Vellucci, Vincent
    Hernandez, Dennis
    McPhee, Fiona
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2016, 71 (12) : 3495 - 3505